The challenge for cancer researchers is now to further clarify whether PKCθ tumoral function is dependent on its kinase activity and to clearly define PKCθ as a new therapeutic target for human cancers such as GIST and aggressive breast cancers. Here, PRRT2 is linked to gastrointestinal stromal tumor.